Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| K-Lens | Experimental | Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug |
|
| Placebo Lens | Placebo Comparator | Placebo lens |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| contact lens with ketotifen | Device | K-Lens (generic name not established) and Ketotifen combination drug-device product |
|
| Measure | Description | Time Frame |
|---|---|---|
| Lid and Lid Margin Erythema, Change From Baseline | Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Lid and Lid Margin Swelling, Change From Baseline | Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Conjunctival Redness, Change From Baseline | Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Conjunctival Chemosis, Change From Baseline | Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Edema, Change From Baseline | Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Erosion, Change From Baseline | Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Endothelial, Change From Baseline | Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brian Pall, OD, MS, FAAO | Johnson & Johnson Vision Care, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Memphis | Tennessee | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | K-Lens | Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug |
| FG001 | Placebo Lens | contact lens without drug |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | K-Lens | Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug |
| BG001 | Placebo Lens | contact lens without drug |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Lid and Lid Margin Erythema, Change From Baseline | Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | K-Lens | Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Benign adenoma | Reproductive system and breast disorders | Non-systematic Assessment | Benign tumor on an ovary, unrelated to test article. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Instillation Site Irritation | Eye disorders | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Brian Pall OD MS FAAO | Vistakon | 904-443-1290 |
Not provided
| ID | Term |
|---|---|
| D003233 | Conjunctivitis, Allergic |
| ID | Term |
|---|---|
| D003231 | Conjunctivitis |
| D003229 | Conjunctival Diseases |
| D005128 | Eye Diseases |
| D006969 | Hypersensitivity, Immediate |
Not provided
Not provided
| ID | Term |
|---|---|
| D003261 | Contact Lenses |
| ID | Term |
|---|---|
| D007909 | Lenses |
| D055096 | Optical Devices |
| D004864 | Equipment and Supplies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| contact lens | Device | Placebo contact lens |
|
| baseline and 12 weeks |
| Lens Pathology, Change From Baseline | Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Flare in Anterior Chamber, Change From Baseline | Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Cells in Anterior Chamber, Change From Baseline | Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Staining - Nasal, Change From Baseline | Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Staining - Temporal, Change From Baseline | Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Staining - Inferior, Change From Baseline | Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Staining - Superior, Change From Baseline | Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Corneal Staining - Central, Change From Baseline | Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | baseline and 12 weeks |
| Intraocular Pressure - Change From Baseline | baseline and 12 weeks |
| Dilated Ophthalmoscopy - Fundus, Change From Baseline | Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. | baseline and 12 weeks |
| Dilated Ophthalmoscopy - Vitreous, Change From Baseline | Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. | baseline and 12 weeks |
| Visual Acuity Assessment | Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit. | at the 12 week visit |
| Protocol Violation |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
| eyes |
|
|
| Primary | Lid and Lid Margin Swelling, Change From Baseline | Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Conjunctival Redness, Change From Baseline | Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Conjunctival Chemosis, Change From Baseline | Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Edema, Change From Baseline | Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Erosion, Change From Baseline | Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Endothelial, Change From Baseline | Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Lens Pathology, Change From Baseline | Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Flare in Anterior Chamber, Change From Baseline | Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Cells in Anterior Chamber, Change From Baseline | Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Staining - Nasal, Change From Baseline | Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Staining - Temporal, Change From Baseline | Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Staining - Inferior, Change From Baseline | Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Staining - Superior, Change From Baseline | Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Corneal Staining - Central, Change From Baseline | Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Intraocular Pressure - Change From Baseline | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | mm of mercury | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Dilated Ophthalmoscopy - Fundus, Change From Baseline | Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Dilated Ophthalmoscopy - Vitreous, Change From Baseline | Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. | Subjects that completed the study per protocol were included in this analysis. | Posted | Mean | Standard Deviation | Units on a scale | baseline and 12 weeks | eyes | Participants |
|
|
|
| Primary | Visual Acuity Assessment | Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit. | Subjects that completed the study per protocol were included in this analysis. | Posted | Number | Eyes | at the 12 week visit | eyes | Participants |
|
|
|
| 1 |
| 168 |
| 12 |
| 168 |
| EG001 | Placebo Lens | contact lens without drug | 0 | 82 | 0 | 82 |
|
| Cholelithiasis | Gastrointestinal disorders | Non-systematic Assessment | Gallstones, unrelated to test article. |
|
Investigator agrees not to publish or publicly present the results of the study without the prior written approval of the sponsor.
| D006967 |
| Hypersensitivity |
| D007154 | Immune System Diseases |